Releases
Corporate Releases, Press Releases, and Features
Stay updated on Lundbeck’s latest company announcements. Subscribe to our releases.
Latest releases
- Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties
- Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
- Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
- ANNOUNCEMENT FOR THE PURPOSES OF ARTICLE 17 "MAR" RULES (EU) NO. 596/2014 (INSIDE INFORMATION) AND RULE 2.8 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”)
- ANNOUNCEMENT FOR THE PURPOSES OF RULE 2.12 OF THE IRISH TAKEOVER PANEL ACT 1997, TAKEOVER RULES, 2022 (THE “IRISH TAKEOVER RULES”) AND MAR ARTICLE 17 (INSIDE INFORMATION)
In order to comply with applicable regulation, press releases concerning a specific medicinal product are removed from our website within three weeks of publication. They can be retained upon request.
More from Lundbeck
Investor Relations
Detailed information related to Lundbeck’s financial performance. Contact Christian Raadmand Jensen, Senior Director, + 45 3083 3704
About Us
A global pharmaceutical company specialized in brain diseases.
Press
Lundbeck seeks an open dialogue with the press. For general press enquiries, please call
+ 45 3643 4000